Physician profile
Leigh D Johnson
NPI 1093917486
$29,840.09
in general payments reported to CMS, 2019-2025
15 companies · $11K in 2025
The $11K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,114 · 2021: $681 · 2022: $6,554 · 2023: $7,485 · 2024: $2,444 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Travel and Lodging: $4,426 · Food and Beverage: $1,599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,466.00 |
| Travel and Lodging | $4,426.28 |
| Food and Beverage | $1,599.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $26,865.57 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,459.47 | 2019-2023 | Gardasil 9, M-M-R II, Vaxelis |
| Abbvie INC. | $313.40 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $297.47 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $252.77 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $174.66 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $129.79 | 2022-2025 | |
| Astellas Pharma US INC | $114.17 | 2023-2024 | Veozah |
| Esperion Therapeutics, INC. | $53.61 | 2021-2023 | Nexletol |
| Exact Sciences Corporation | $50.91 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceutical Holding Company Ltd. | $41.59 | 2022 | |
| Glaxosmithkline, LLC. | $36.51 | 2022-2023 | Shingrix |
| Axsome Therapeutics, INC. | $20.85 | 2025 | Auvelity |
| Amgen INC. | $15.82 | 2023 | Evenity, Prolia |
| Exeltis, USA INC. | $13.50 | 2024 | Slynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leigh Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.